Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

NCT00913367 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: glimepiride + insulin glargine (Amaryl + Lantus)
DRUG: glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)

Sponsor

Handok Inc.